Prograf
Designed to mitigate transplant rejection to support long-term organ health.
Strengths: 0.5 · 1 · 5mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Adoport
- Therapeutic class
Immunosuppressant
- Pharmacological class
Calcineurin Inhibitor
- Contraindications
hypersensitivity to tacrolimus; hypersensitivity to macrolides
- Minor side effects
tremor; headache
- Moderate side effects
hypertension; renal impairment; abnormal liver function tests
- Dosage forms
Capsule, hard
- Administration route
Oral use
- Patient summary
Designed to mitigate transplant rejection to support long-term organ health.
- Prescription status
POM
- Manufacturer
Astellas Pharma
- Onset Time
1–2 hours
- Duration
12 hours
- Storage instructions
Store in the original blister package.
- Drug interactions
grapefruit; ketoconazole; rifampicin
- Age restrictions
Adjusted for weight in paediatric patients.
Precautions and warnings
regular blood monitoring required; avoid excessive sun exposure; monitor kidney function
Serious side effects
opportunistic infections — requires immediate medical attention; lymphoma — requires immediate medical attention
Mechanism of action
Suppresses the immune response by inhibiting calcineurin, thereby preventing the activation of T-cells that trigger organ rejection.
Pregnancy and breastfeeding
Pregnancy: Avoid unless deemed essential by a specialist. Breastfeeding: Not recommended.
Prograf
Designed to mitigate transplant rejection to support long-term organ health.
Editorial Notes
- Active ingredient(s): Tacrolimus
- Listed indication(s): Transplant Rejection
Usually available as
- 30 tablets - 0.5 mg83-0-5-mg-1388
- 20 tablets - 1 mg83-1-mg-1379
- 10 tablets - 5 mg83-5-mg-1383